Fujian Cosunter Pharmaceutical Co Ltd banner
F

Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436

Watchlist Manager
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
Watchlist
Price: 123.05 CNY -3.83% Market Closed
Market Cap: ¥19.6B

Relative Value

The Relative Value of one Fujian Cosunter Pharmaceutical Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 123.05 CNY, Fujian Cosunter Pharmaceutical Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Fujian Cosunter Pharmaceutical Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Fujian Cosunter Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
19.6B CNY 45.5 -99.4 -123.9 -123.9
US
Eli Lilly and Co
NYSE:LLY
979.9B USD 15.3 48.4 32.6 34.7
US
Johnson & Johnson
NYSE:JNJ
590.5B USD 6.3 22.1 15.4 18.9
CH
Roche Holding AG
SIX:ROG
298.2B CHF 4.9 31.7 13.3 15.6
UK
AstraZeneca PLC
LSE:AZN
240.7B GBP 5.5 31.8 17.5 24.6
CH
Novartis AG
SIX:NOVN
247.5B CHF 5.7 22.8 14 18.1
US
Merck & Co Inc
NYSE:MRK
306.4B USD 4.8 16.9 10.5 12.3
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.5 10.7 7.9 9.3
US
Pfizer Inc
NYSE:PFE
155.3B USD 2.5 20 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
123.2B USD 2.6 17.6 7.3 9.1
P/E Multiple
Earnings Growth PEG
CN
F
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
Average P/E: 24.7
Negative Multiple: -99.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.4
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22.1
7%
3.2
CH
Roche Holding AG
SIX:ROG
31.7
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.8
26%
1.2
CH
Novartis AG
SIX:NOVN
22.8
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.9
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
7%
1.5
US
Pfizer Inc
NYSE:PFE
20
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.6
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
F
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
Average EV/EBITDA: 45.9
Negative Multiple: -123.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.6
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.4
2%
7.7
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
17.5
11%
1.6
CH
Novartis AG
SIX:NOVN
14
9%
1.6
US
Merck & Co Inc
NYSE:MRK
10.5
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.9
7%
1.1
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-12%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
F
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
Average EV/EBIT: 98.8
Negative Multiple: -123.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.7
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.9
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.6
6%
2.6
UK
AstraZeneca PLC
LSE:AZN
24.6
24%
1
CH
Novartis AG
SIX:NOVN
18.1
12%
1.5
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
8%
1.2
US
Pfizer Inc
NYSE:PFE
9.9
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.1
-6%
N/A